Loading
Latest filing published 02 Oct 2026 for Compass Therapeutics, Inc., €16k. Read the official filing
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
All filings by Neil Lerner on record concern Compass Therapeutics, Inc. We count 6 filings; the first trade dates from 7 April 2025 and the latest from 1 October 2026.
Every open-market trade on record is a purchase: 4 purchases worth €69k, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 2 share grants. In 2026 alone, the filings show 3 purchases and no sales.
Half of the purchases are above €20k and half below. Relative to company size, the median is 0.0080% of market cap (3 purchases with a known value). On 1 out of 3 purchases, another insider of the same company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.
The newest entry dates from 2 October 2026: an open-market purchase of €16k, in Compass Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
6 of 6 declarations